Characterisation of CASPR2 deficiency disorder - a syndrome involving autism, epilepsy and language impairment

Pedro Rodenas-Cuadrado, Nicola Pietrafusa, Teresa Francavilla, Angela La Neve, Pasquale Striano, Sonja C. Vernes

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex phenotypes including intellectual disability, autism and schizophrenia. However heterozygous CNTNAP2 mutations are also found in the normal population. Conversely, homozygous mutations are rare in patient populations and have not been found in any unaffected individuals. Case presentation: We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish function of its protein product, CASPR2. Homozygous family members display epilepsy, facial dysmorphisms, severe intellectual disability and impaired language. We compared these patients with previously reported individuals carrying homozygous mutations in CNTNAP2 and identified a highly recognisable phenotype. Conclusions: We propose that CASPR2 loss produces a syndrome involving early-onset refractory epilepsy, intellectual disability, language impairment and autistic features that can be recognized as CASPR2 deficiency disorder. Further screening for homozygous patients meeting these criteria, together with detailed phenotypic and molecular investigations will be crucial for understanding the contribution of CNTNAP2 to normal and disrupted development.

Original languageEnglish
JournalBMC Medical Genetics
DOIs
Publication statusAccepted/In press - Feb 3 2016

Fingerprint

Autistic Disorder
Epilepsy
Language
Intellectual Disability
Mutation
Phenotype
Population
Schizophrenia
Proteins

Keywords

  • Autism
  • CNTNAP2
  • Epilepsy
  • Intellectual disability
  • Language regression

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Characterisation of CASPR2 deficiency disorder - a syndrome involving autism, epilepsy and language impairment. / Rodenas-Cuadrado, Pedro; Pietrafusa, Nicola; Francavilla, Teresa; La Neve, Angela; Striano, Pasquale; Vernes, Sonja C.

In: BMC Medical Genetics, 03.02.2016.

Research output: Contribution to journalArticle

Rodenas-Cuadrado, Pedro ; Pietrafusa, Nicola ; Francavilla, Teresa ; La Neve, Angela ; Striano, Pasquale ; Vernes, Sonja C. / Characterisation of CASPR2 deficiency disorder - a syndrome involving autism, epilepsy and language impairment. In: BMC Medical Genetics. 2016.
@article{25ac489c538242f9ba866d5f81cc64a7,
title = "Characterisation of CASPR2 deficiency disorder - a syndrome involving autism, epilepsy and language impairment",
abstract = "Background: Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex phenotypes including intellectual disability, autism and schizophrenia. However heterozygous CNTNAP2 mutations are also found in the normal population. Conversely, homozygous mutations are rare in patient populations and have not been found in any unaffected individuals. Case presentation: We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish function of its protein product, CASPR2. Homozygous family members display epilepsy, facial dysmorphisms, severe intellectual disability and impaired language. We compared these patients with previously reported individuals carrying homozygous mutations in CNTNAP2 and identified a highly recognisable phenotype. Conclusions: We propose that CASPR2 loss produces a syndrome involving early-onset refractory epilepsy, intellectual disability, language impairment and autistic features that can be recognized as CASPR2 deficiency disorder. Further screening for homozygous patients meeting these criteria, together with detailed phenotypic and molecular investigations will be crucial for understanding the contribution of CNTNAP2 to normal and disrupted development.",
keywords = "Autism, CNTNAP2, Epilepsy, Intellectual disability, Language regression",
author = "Pedro Rodenas-Cuadrado and Nicola Pietrafusa and Teresa Francavilla and {La Neve}, Angela and Pasquale Striano and Vernes, {Sonja C.}",
year = "2016",
month = "2",
day = "3",
doi = "10.1186/s12881-016-0272-8",
language = "English",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Characterisation of CASPR2 deficiency disorder - a syndrome involving autism, epilepsy and language impairment

AU - Rodenas-Cuadrado, Pedro

AU - Pietrafusa, Nicola

AU - Francavilla, Teresa

AU - La Neve, Angela

AU - Striano, Pasquale

AU - Vernes, Sonja C.

PY - 2016/2/3

Y1 - 2016/2/3

N2 - Background: Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex phenotypes including intellectual disability, autism and schizophrenia. However heterozygous CNTNAP2 mutations are also found in the normal population. Conversely, homozygous mutations are rare in patient populations and have not been found in any unaffected individuals. Case presentation: We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish function of its protein product, CASPR2. Homozygous family members display epilepsy, facial dysmorphisms, severe intellectual disability and impaired language. We compared these patients with previously reported individuals carrying homozygous mutations in CNTNAP2 and identified a highly recognisable phenotype. Conclusions: We propose that CASPR2 loss produces a syndrome involving early-onset refractory epilepsy, intellectual disability, language impairment and autistic features that can be recognized as CASPR2 deficiency disorder. Further screening for homozygous patients meeting these criteria, together with detailed phenotypic and molecular investigations will be crucial for understanding the contribution of CNTNAP2 to normal and disrupted development.

AB - Background: Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex phenotypes including intellectual disability, autism and schizophrenia. However heterozygous CNTNAP2 mutations are also found in the normal population. Conversely, homozygous mutations are rare in patient populations and have not been found in any unaffected individuals. Case presentation: We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish function of its protein product, CASPR2. Homozygous family members display epilepsy, facial dysmorphisms, severe intellectual disability and impaired language. We compared these patients with previously reported individuals carrying homozygous mutations in CNTNAP2 and identified a highly recognisable phenotype. Conclusions: We propose that CASPR2 loss produces a syndrome involving early-onset refractory epilepsy, intellectual disability, language impairment and autistic features that can be recognized as CASPR2 deficiency disorder. Further screening for homozygous patients meeting these criteria, together with detailed phenotypic and molecular investigations will be crucial for understanding the contribution of CNTNAP2 to normal and disrupted development.

KW - Autism

KW - CNTNAP2

KW - Epilepsy

KW - Intellectual disability

KW - Language regression

UR - http://www.scopus.com/inward/record.url?scp=84956640101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956640101&partnerID=8YFLogxK

U2 - 10.1186/s12881-016-0272-8

DO - 10.1186/s12881-016-0272-8

M3 - Article

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

ER -